| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| T S Pronina, A A Kolacheva, L K Dil'muhametova, Yu O Nikishina, K K Suhinich, M V Ugrumo. Characteristic of Dopamine-Producing System and Dopamine Receptors in the Suprachiasmatic Nucleus in Rats in Ontogenesis. Doklady. Biochemistry and biophysics. vol 490. issue 1. 2021-01-26. PMID:32342310. |
one of the features of the developing suprachiasmatic nucleus (scn), the "biological clock" of the body, is the early expression of dopamine (da) receptors in the absence of dopaminergic neurons as a source of da. |
2021-01-26 |
2023-08-13 |
rat |
| Patrycja Kupnicka, Klaudyna Kojder, Emilia Metryka, Patrycja Kapczuk, Dariusz Jeżewski, Izabela Gutowska, Marta Goschorska, Dariusz Chlubek, Irena Baranowska-Bosiack. Morphine-element interactions - The influence of selected chemical elements on neural pathways associated with addiction. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS). vol 60. 2021-01-25. PMID:32179426. |
mesolimbic and mesocortical dopaminergic pathways play an important role in modulation of cognitive processes and decision making and, therefore, changes in dopamine metabolism are considered the central basis for the development of dependence. |
2021-01-25 |
2023-08-13 |
Not clear |
| Fangmiao Sun, Jingheng Zhou, Bing Dai, Tongrui Qian, Jianzhi Zeng, Xuelin Li, Yizhou Zhuo, Yajun Zhang, Yipan Wang, Cheng Qian, Ke Tan, Jiesi Feng, Hui Dong, Dayu Lin, Guohong Cui, Yulong L. Next-generation GRAB sensors for monitoring dopaminergic activity in vivo. Nature methods. vol 17. issue 11. 2021-01-25. PMID:33087905. |
dopamine (da) plays a critical role in the brain, and the ability to directly measure dopaminergic activity is essential for understanding its physiological functions. |
2021-01-25 |
2023-08-13 |
Not clear |
| Wen-Wen Liu, Shi-Zhuang Wei, Guo-Dong Huang, Lu-Bing Liu, Chao Gu, Yun Shen, Xian-Hui Wang, Shu-Ting Xia, An-Mu Xie, Li-Fang Hu, Fen Wang, Chun-Feng Li. BMAL1 regulation of microglia-mediated neuroinflammation in MPTP-induced Parkinson's disease mouse model. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. vol 34. issue 5. 2021-01-22. PMID:32246801. |
we here showed that inactivation of brain and muscle arnt-like 1 (bmal1) in 1-methyl-4-phenyl-1,2,4,5-tetrahydropyridine (mptp)-treated mice resulted in obvious motor functional deficit, loss of dopaminergic neurons (dans) in the substantia nigra pars compacta (snpc), decrease of dopamine (da) transmitter, and increased activation of microglia and astrocytes in the striatum. |
2021-01-22 |
2023-08-13 |
mouse |
| Joseph Jankovic, Eng King Ta. Parkinson's disease: etiopathogenesis and treatment. Journal of neurology, neurosurgery, and psychiatry. vol 91. issue 8. 2021-01-19. PMID:32576618. |
the involvement of dopaminergic as well as noradrenergic, glutamatergic, serotonergic and adenosine pathways provide insights into the rich and variable clinical phenomenology associated with pd and the possibility of alternative therapeutic approaches beyond traditional dopamine replacement therapies.one of the biggest challenges in the development of potential neuroprotective therapies has been the lack of reliable and sensitive biomarkers of progression. |
2021-01-19 |
2023-08-13 |
Not clear |
| Bianca L B Marino, Lucilene R de Souza, Kessia P A Sousa, Jaderson V Ferreira, Elias C Padilha, Carlos H T P da Silva, Carlton A Taft, Lorane I S Hage-Meli. Parkinson's Disease: A Review from Pathophysiology to Treatment. Mini reviews in medicinal chemistry. vol 20. issue 9. 2021-01-15. PMID:31686637. |
pd is caused by the necrosis of dopaminergic neurons in the substantia nigra, which is the brain region responsible for the synthesis of the neurotransmitter dopamine (da), resulting in its decrease in the synaptic cleft. |
2021-01-15 |
2023-08-13 |
Not clear |
| Wanpeng Cui, Tomomi Aida, Hikaru Ito, Kenta Kobayashi, Yusaku Wada, Shigeki Kato, Takashi Nakano, Meina Zhu, Kaoru Isa, Kazuto Kobayashi, Tadashi Isa, Kohichi Tanaka, Hidenori Aizaw. Dopaminergic Signaling in the Nucleus Accumbens Modulates Stress-Coping Strategies during Inescapable Stress. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 40. issue 38. 2021-01-15. PMID:32847967. |
to investigate how dopamine signaling modulates stress-coping behavior, we measured the subsecond fluctuation of extracellular dopamine concentration and ph using fast scanning cyclic voltammetry (fscv) in the nac, a postsynaptic target of midbrain dopaminergic neurons, in male mice engaged in a tail suspension test (tst). |
2021-01-15 |
2023-08-13 |
mouse |
| Wanpeng Cui, Tomomi Aida, Hikaru Ito, Kenta Kobayashi, Yusaku Wada, Shigeki Kato, Takashi Nakano, Meina Zhu, Kaoru Isa, Kazuto Kobayashi, Tadashi Isa, Kohichi Tanaka, Hidenori Aizaw. Dopaminergic Signaling in the Nucleus Accumbens Modulates Stress-Coping Strategies during Inescapable Stress. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 40. issue 38. 2021-01-15. PMID:32847967. |
we then addressed the causal relationship of such a dopaminergic transmission with behavioral alterations by knocking out both the dopamine receptors, i.e., d1 and d2, in the nac using viral vector-mediated genome editing. |
2021-01-15 |
2023-08-13 |
mouse |
| Maria Lindahl, Alcmène Chalazonitis, Erik Palm, Emmi Pakarinen, Tatiana Danilova, Tuan D Pham, Wanda Setlik, Meenakshi Rao, Vootele Võikar, Jatta Huotari, Jaakko Kopra, Jaan-Olle Andressoo, Petteri T Piepponen, Mikko Airavaara, Anne Panhelainen, Michael D Gershon, Mart Saarm. Cerebral dopamine neurotrophic factor-deficiency leads to degeneration of enteric neurons and altered brain dopamine neuronal function in mice. Neurobiology of disease. vol 134. 2021-01-13. PMID:31783118. |
cerebral dopamine neurotrophic factor (cdnf) is neuroprotective for nigrostriatal dopamine neurons and restores dopaminergic function in animal models of parkinson's disease (pd). |
2021-01-13 |
2023-08-13 |
mouse |
| Carlos Juri, Vasko Kramer, Patrick J Riss, Cristian Soza-Ried, Arlette Haeger, Rossana Pruzzo, Frank Rösch, Horacio Amaral, Pedro Chana-Cueva. [18F]PR04.MZ PET/CT Imaging for Evaluation of Nigrostriatal Neuron Integrity in Patients With Parkinson Disease. Clinical nuclear medicine. vol 46. issue 2. 2021-01-13. PMID:33323728. |
degeneration of dopaminergic, nigrostriatal neurons is the hallmark of parkinson disease (pd), and pet quantification of dopamine transporters is a widely accepted method for differential diagnosis between idiopathic pd and essential tremor. |
2021-01-13 |
2023-08-13 |
Not clear |
| M Angela Cenci, Anders Björklun. Animal models for preclinical Parkinson's research: An update and critical appraisal. Progress in brain research. vol 252. 2021-01-11. PMID:32247366. |
a substantial loss of nigrostriatal dopamine neurons is necessary for the animal to exhibit a hypokinetic motor phenotype responsive to dopaminergic agents, thus resembling clinical pd. |
2021-01-11 |
2023-08-13 |
mouse |
| Hirotaka Sekiguchi, Geoff Pavey, Brian Dea. Altered levels of dopamine transporter in the frontal pole and dorsal striatum in schizophrenia. NPJ schizophrenia. vol 5. issue 1. 2021-01-10. PMID:31792225. |
we postulated that the dopamine transporter (dat), which regulates intra-synaptic dopamine concentrations by transporting dopamine from the synaptic cleft into the pre-synaptic neuron, could be involved in dopaminergic dysfunction in schizophrenia. |
2021-01-10 |
2023-08-13 |
human |
| Fabin Han, Baoyang H. Stem Cell Therapy for Parkinson's Disease. Advances in experimental medicine and biology. vol 1266. 2021-01-08. PMID:33105493. |
here, we summarize the research advance in experimental and clinical studies to transplant these cells into animal models and clinical patients, and specifically highlight the studies to use hescs /ipscs-derived dopaminergic precursor cells and dopamine neurons for the treatment of pd, at last propose future challenges for developing clinical-grade dopaminergic cells for treating the pd. |
2021-01-08 |
2023-08-13 |
human |
| Ioannis Mantas, Yunting Yang, Clotilde Mannoury-la-Cour, Mark J Millan, Xiaoqun Zhang, Per Svenningsso. Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia. Neuropharmacology. vol 162. 2021-01-06. PMID:31666199. |
parkinson's disease (pd) is characterized by progressive loss of midbrain dopaminergic neurons and treated with the dopamine precursor, 3,4-dihydroxy-l-phenylalanine (l-dopa). |
2021-01-06 |
2023-08-13 |
mouse |
| A J Robison, Katharine N Thakkar, Vaibhav A Diwadka. Cognition and Reward Circuits in Schizophrenia: Synergistic, Not Separate. Biological psychiatry. vol 87. issue 3. 2021-01-06. PMID:31733788. |
we then expand on the role of glutamatergic inputs to these dopamine circuits and dopaminergic modulation of critical excitatory pathways with attention given to the role of glutamatergic hippocampal outputs onto nucleus accumbens. |
2021-01-06 |
2023-08-13 |
human |
| Yu-Chia Chen, Diego Baronio, Svetlana Semenova, Shamsiiat Abdurakhmanova, Pertti Panul. Cerebral Dopamine Neurotrophic Factor Regulates Multiple Neuronal Subtypes and Behavior. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 40. issue 32. 2021-01-04. PMID:32631936. |
cerebral dopamine neurotrophic factor (cdnf) protects dopaminergic neurons against toxic damage in the rodent brain and is in clinical trials to treat parkinson's disease patients. |
2021-01-04 |
2023-08-13 |
zebrafish |
| Fillipe M de Araújo, Lorena Cuenca-Bermejo, Emiliano Fernández-Villalba, Silvia L Costa, Victor Diogenes A Silva, Maria Trinidad Herrer. Role of Microgliosis and NLRP3 Inflammasome in Parkinson's Disease Pathogenesis and Therapy. Cellular and molecular neurobiology. 2021-01-02. PMID:33387119. |
parkinson's disease (pd) is a neurodegenerative disorder marked primarily by motor symptoms such as rigidity, bradykinesia, postural instability and resting tremor associated with dopaminergic neuronal loss in the substantia nigra pars compacta (snpc) and deficit of dopamine in the basal ganglia. |
2021-01-02 |
2023-08-13 |
Not clear |
| Michael Silkstone, Stefan M Brudzynsk. Dissimilar interaction between dopaminergic and cholinergic systems in the initiation of emission of 50-kHz and 22-kHz vocalizations. Pharmacology, biochemistry, and behavior. vol 188. 2020-12-31. PMID:31655084. |
emission of 50-khz usvs is dependent upon the activation of dopaminergic neurons located within the ventral tegmental area that release dopamine into the medial shell of the nucleus accumbens. |
2020-12-31 |
2023-08-13 |
rat |
| Nikita Katila, Sunil Bhurtel, Pil-Hoon Park, Jin Tae Hong, Dong-Young Cho. Activation of AMPK/aPKCζ/CREB pathway by metformin is associated with upregulation of GDNF and dopamine. Biochemical pharmacology. vol 180. 2020-12-31. PMID:32800853. |
parkinson's disease (pd) is the second most common neurodegenerative disease, which is characterized by the progressive loss of dopaminergic neurons in the substantia nigra, leading to a decrease in striatal dopamine. |
2020-12-31 |
2023-08-13 |
mouse |
| Ali Gheidi, Lora M Cope, Christopher J Fitzpatrick, Benjamin N Froehlich, Rachel Atkinson, Coltrane K Groves, Clair N Barcelo, Jonathan D Morro. Effects of the cannabinoid receptor agonist CP-55,940 on incentive salience attribution. Psychopharmacology. vol 237. issue 9. 2020-12-30. PMID:32494975. |
recent evidence has shown that activity of the endocannabinoid system increases dopaminergic activity in the mesocorticolimbic system, and other studies have shown that sign-tracking behaviors are dependent on dopamine. |
2020-12-30 |
2023-08-13 |
Not clear |